Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunoprecipitation01:20

Immunoprecipitation

6.0K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
6.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

725
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treating depression through G proteins.

Science signalingΒ·2026
Same author

Sense and stromal density.

Science signalingΒ·2026
Same author

In Science Journals.

Science (New York, N.Y.)Β·2026
Same author

In Science Journals.

Science (New York, N.Y.)Β·2026
Same author

Neuron-tumor synapses drive PDAC.

Science signalingΒ·2026
Same author

Skewing p53 to tumor-suppressor targets.

Science signalingΒ·2025
Same journal

ZNRF3 and RNF43 are active monomeric E3 ubiquitin ligases that self-associate.

Science signalingΒ·2026
Same journal

Allosteric ligands with distinct properties uncover tissue-specific physiological regulation mediated by free fatty acid receptor 2.

Science signalingΒ·2026
Same journal

Diacylglycerol kinase ΞΆ in B lymphocytes supports CD40-mediated immune synapse formation, mTORC1 signaling, and plasma cell fate.

Science signalingΒ·2026
Same journal

The APC/C adaptor Cdh1 stabilizes STING to potentiate innate immune activation in renal cell carcinoma.

Science signalingΒ·2026
Same journal

Fattening mother's milk with oxytocin.

Science signalingΒ·2026
Same journal

Virion display reveals MD-1 as an endogenous agonist for the orphan receptor GPRC5B.

Science signalingΒ·2026
See all related articles

Related Experiment Video

Updated: Oct 11, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K

Refining precision immunotherapy.

Leslie K Ferrarelli1

  • 1Science Signaling, AAAS, Washington, DC 20005, USA.

Science Signaling
|December 2, 2021
PubMed
Summary
This summary is machine-generated.

Two studies reveal why some DNA mismatch repair deficient (MMRd) tumors respond to immunotherapy, while others do not. This research clarifies the complex relationship between MMR status and treatment efficacy in cancer immunotherapy.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K

Related Experiment Videos

Last Updated: Oct 11, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • DNA mismatch repair deficiency (MMRd) is a biomarker for immunotherapy response.
  • However, not all MMRd tumors exhibit sensitivity to immune checkpoint inhibitors.
  • The underlying mechanisms for this variable response remain incompletely understood.

Purpose of the Study:

  • To investigate the molecular factors determining immunotherapy sensitivity in MMRd tumors.
  • To elucidate the reasons behind differential responses to immunotherapy in MMR-deficient cancer patients.

Main Methods:

  • Analysis of two independent cohorts of MMR-deficient tumors.
  • Genomic and transcriptomic profiling of tumor samples.
  • Correlation of molecular features with clinical response to immunotherapy.

Main Results:

  • Identified specific genetic alterations and immune microenvironment characteristics associated with immunotherapy response in MMRd tumors.
  • Demonstrated that the degree and type of MMR deficiency influence sensitivity.
  • Found distinct molecular signatures between responsive and non-responsive MMRd tumors.

Conclusions:

  • The sensitivity of MMR-deficient tumors to immunotherapy is multifactorial, depending on specific genetic and immune context.
  • These findings provide critical insights for patient stratification and treatment selection in cancer immunotherapy.